Efficacy and Safety of Two Doses of HIL-214 in Children
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05281094 |
|
Recruitment Status :
Recruiting
First Posted : March 16, 2022
Last Update Posted : February 24, 2023
|
Sponsor:
HilleVax
Information provided by (Responsible Party):
HilleVax
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized, placebo-controlled study that is being done to evaluate the safety and effectiveness of two doses of the HIL-214 vaccine compared to a placebo. The study will enroll 3000 children who will be 5 months of age at the time of the first dose study vaccine. The second dose of study vaccine will be given 28 days after the first dose.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Gastroenteritis | Biological: HIL-214 Biological: Placebo | Phase 2 Phase 3 |
Noroviruses have emerged as the single most significant cause of gastroenteritis in both middle-high income countries and low resource settings worldwide. Those most at risk of severe illness include the very young, the elderly and immunocompromised individuals. Noroviruses are highly infectious, highly resistant to environmental conditions, and have multiple routes of transmission including person-to-person, food-borne and contaminated surfaces. Noroviruses can cause acute, mild to severe illness characterized by vomiting, diarrhea, fever, dehydration and abdominal pain, representing a significant burden to public health. The clinical presentation in adults and older children is similar. While mortality due to acute gastroenteritis (AGE) caused by norovirus in the pediatric population is rare in industrialized countries, it is more common in developing countries. Although potentially a cause for hospitalization in very young children, there are fewer cases during the first 6 months of life possibly due to the protection offered by maternal antibodies from trans-placental transfer and in breast milk. In addition, norovirus infections have significant socioeconomic impact on hospitals, schools, day care centers and other closed settings. As the burden of rotavirus in children decreases due to successful rotavirus vaccination programs in infants, norovirus infections are increasingly recognized as the primary cause of AGE in many countries around the world.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 3000 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination |
| Actual Study Start Date : | March 16, 2022 |
| Estimated Primary Completion Date : | March 17, 2023 |
| Estimated Study Completion Date : | June 11, 2024 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
One dose of placebo on Day 1 and one dose of placebo between Day 29 and Day 57.
|
Biological: Placebo
2 injections - given on Day 1 and the second given between Day 29 - Day 57 |
|
Experimental: Experimental
One dose of HIL-214 on Day 1 and one dose of HIL-214 between Day 29 and Day 57.
|
Biological: HIL-214
2 injections - given on Day 1 and the second given between Day 29 - Day 57 |
Primary Outcome Measures :
- Primary Objective [ Time Frame: From 4 weeks after second vaccination through the end of the surveillance period ]The number of subjects with moderate to severe AGE cases associated with GI.1 or GII.4 NoV genotypes.
Secondary Outcome Measures :
- Key Secondary Objective [ Time Frame: From 4 weeks after second vaccination through the end of the surveillance period ]The number of subjects with moderate to severe AGE cases associated with GI.1 or GII.4 NoV genotypes.
Other Outcome Measures:
- Immunogenicity Objectives [ Time Frame: Through 28 days post Dose 2 ]Titer results for HBGA blocking antibody test
- Immunogenicity Objectives - Secondary [ Time Frame: Through 28 days post Dose 2 ]Titer results for Pan-Ig antibody test
- Solicited Local AEs [ Time Frame: Up to 7 days after each dose ]The number of subjects with solicited local AEs
- Solicited Systemic AEs [ Time Frame: Up to 7 days after each dose ]The number of subjects with solicited systemic AEs
- Unsolicited Symptomatic AEs [ Time Frame: Up to 28 days after each dose ]The number of subjects with unsolicited symptoms AEs
- AEs Leading to Withdrawal [ Time Frame: Up to 28 days after each dose ]The number AEs that lead to vaccine dose withdrawal
- Adverse Events and Serious Adverse Events [ Time Frame: Day 1 through end of trial, up to 2 years ]The number of AEs and SAEs that lead to the subject's withdrawal from the trial
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Months to 5 Months (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria
- The subject should be 5 months of age (within plus or minus 14 days) male or female
- Children who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator
- The subject's LAR signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements
- Children whose LARs can and are willing to comply with trial procedures and are available for the duration of follow-up
Exclusion Criteria
- Clinically significant abnormality in growth by height, weight, or head circumference (according to local guidelines)
- Gastrointestinal abnormalities or any chronic gastrointestinal disease, including any uncorrected congenital malformation of the gastrointestinal tract according to medical history and/or physical examination
- Known hypersensitivity or allergy to any of the investigational vaccine components (including excipients)
- Any clinically significant active infection (as assessed by the investigator) or temperature ≥38.0°C (>100.4°F), within 3 days of intended trial vaccination
- Any serious chronic or progressive disease according to the judgment of the investigator (e.g., cardiac, renal or hepatic disease)
- Individuals with history of, e.g., convulsions/febrile convulsions, or any illness, that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the subjects due to participation in the trial
- Known or suspected impairment/alteration of immune function
- Subjects with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
- Subjects who received or are scheduled to receive any other vaccines within 14 days (for inactivated vaccines and oral polio vaccine) or 28 days (for other live vaccines) before or after any dose of trial vaccine
- Subjects participating in any clinical trial with another investigational product 30 days prior to first trial visit or intend to participate in another clinical trial at any time during the conduct of this trial
- Subjects known to be positive for or in evaluation for possible human immunodeficiency virus infection
- Subject's LAR or subject's first-degree relatives involved in the trial conduct
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05281094
Contacts
| Contact: Clinical Lead | 617-203-7722 | clinical.trials@hillevax.com |
Locations
Show 23 study locations
Sponsors and Collaborators
HilleVax
| Responsible Party: | HilleVax |
| ClinicalTrials.gov Identifier: | NCT05281094 |
| Other Study ID Numbers: |
NOR-212 |
| First Posted: | March 16, 2022 Key Record Dates |
| Last Update Posted: | February 24, 2023 |
| Last Verified: | February 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |